Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any Ehlers-Danlos syndrome, spondylodysplastic type in which the cause of the disease is a mutation in the B3GALT6 gene.
Features include always present findings: Short stature, Large joint hypermobilty, Prominent forehead, and Kyphoscoliosis and others; and very common findings: Increased susceptibility to fractures, Mild bone density loss (osteopenia), and Soft skin. 50 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Bones and joints | 13 | Large joint hypermobilty, Increased susceptibility to fractures, Kyphoscoliosis |
Muscles | 3 | Low muscle tone (hypotonia), Joint contracture, Joint contracture of the hand |
Head and neck | 3 | Long upper lip, Cleft palate, Flat face |
Skin | 3 | Soft skin, Soft, doughy skin, Hyperextensible skin |
Arms and legs | 2 | Finger joint hypermobility, Joint contracture of the hand |
Growth and development | 1 | Short stature |
Heart and blood vessels | 1 | Aortic root aneurysm |
Brain and nerves | 1 | Global developmental delay |
Lungs and breathing | 1 | Difficulty breathing (respiratory insufficiency) |
B3GALT6 encodes beta-1,3-galactosyltransferase 6 (329 aa). Beta-1,3-galactosyltransferase that transfers galactose from UDP-galactose to substrates with a terminal beta-linked galactose residue. Highest expression in Cells Cultured fibroblasts (29.9 TPM) and Uterus (23.1 TPM).
Ehlers-Danlos syndrome, spondylodysplastic type, 2 is associated with mutations in the B3GALT6 gene on chromosome 1.
The B3GALT6 protein participates in B3GALT6 R197Afs*81 and Defective B3GALT6 causes EDSP2 and SEMDJL1 pathways.
B3GALT6 is classified as a druggable target (Enzyme category) with score 0.0.
Genetic testing for B3GALT6 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 17 always present features, 3 very common features, 19 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for Ehlers-Danlos syndrome, spondylodysplastic type, 2.
3 publications have been identified in PubMed for Ehlers-Danlos syndrome, spondylodysplastic type, 2. Research spans Review / Meta-Analysis (33%), Case Report / Case Series (33%), and Basic Science / Preclinical (33%).
Weidler S (2026). [PMID: 41316887](https://pubmed.ncbi.nlm.nih.gov/41316887/). *Angew Chem Int Ed Engl*. [Basic Science / Preclinical]
Maheshati A (2025). [PMID: 40371684](https://pubmed.ncbi.nlm.nih.gov/40371684/). *Orthop Surg*. [Review / Meta-Analysis]
Lan S (2025). [PMID: 41811047](https://pubmed.ncbi.nlm.nih.gov/41811047/). *Zhonghua Yi Xue Yi Chuan Xue Za Zhi*. [Case Report / Case Series]
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 6:58 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Ehlers-Danlos syndrome, spondylodysplastic type, 2